Laura C. Michaelis, MD: In My Experience Question 3

Giorgio V. Scagliotti, MD, PhD, on the Ongoing Battle Against COVID-19: Update From Italy

Giorgio V. Scagliotti, MD, PhD, of the University of Turin, talks about the ways in which coronavirus reshaped Italian hospitals, mistakes made, and lessons learned. Filmed April 15, 2020.

COVID-19

The ASCO Post Staff

Karen E. Knudsen, PhD, MBA, on Delivering Cancer Care During the COVID-19 Pandemic: Report From Philadelphia

Karen E. Knudsen, PhD, MBA, Director of the Sidney Kimmel Cancer Center, talks about what she and her staff have encountered during the COVID-19 crisis and how they and their patients are coping. Filmed March 25, 2020.

Multiple Myeloma

COVID-19

The ASCO Post Staff

Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.

COVID-19

The ASCO Post Staff

Nancy E. Davidson, MD, on COVID-19 and Cancer Care: Thoughts From the Seattle Epicenter

Nancy E. Davidson, MD, of the Seattle Cancer Care Alliance, and a member of The ASCO Post Editorial Board, talks about her experiences in one of the communities hardest hit by coronavirus and offers some practical advice on making changes in treatment and research. Recorded April 7, 2020.

COVID-19

Immunotherapy

The ASCO Post Staff

Joseph C. Alvarnas, MD, on the Increased Risk of Side Effects for Patients With Cancer and COVID-19

Joseph C. Alvarnas, MD, of the City of Hope National Medical Center, discusses the patients with cancer who are at an increased risk for developing serious complications from COVID-19, including those receiving bone marrow or stem cell transplants and CAR-T cell therapy, and what they can do to protect themselves. Filmed April 17, 2020.

Nov

Today In Oncology

Laura C. Michaelis, MD: In My Experience Question 3

Related Videos

Giorgio V. Scagliotti, MD, PhD, on the Ongoing Battle Against COVID-19: Update From Italy

Karen E. Knudsen, PhD, MBA, on Delivering Cancer Care During the COVID-19 Pandemic: Report From Philadelphia

Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

Nancy E. Davidson, MD, on COVID-19 and Cancer Care: Thoughts From the Seattle Epicenter

Joseph C. Alvarnas, MD, on the Increased Risk of Side Effects for Patients With Cancer and COVID-19

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma